Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Alterations in the gut microbiome after transjugular intrahepatic portosystemic shunt in patients with hepatitis B virus-related portal hypertension.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
- Publication Information:
Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
Original Publication: Beijing : WJG Press, c1998-
- Subject Terms:
- Abstract:
Background: Gut microbiota (GM) affects the progression and response to treatment in liver diseases. The GM composition is diverse and associated with different etiologies of liver diseases. Notably, alterations in GM alterations are observed in patients with portal hypertension (PH) secondary to cirrhosis, with hepatitis B virus (HBV) infection being a major cause of cirrhosis in China. Thus, understanding the role of GM alterations in patients with HBV infection-related PH is essential.
Aim: To evaluate GM alterations in patients with HBV-related PH after transjugular intrahepatic portosystemic shunt (TIPS) placement.
Methods: This was a prospective, observational clinical study. There were 30 patients (with a 100% technical success rate) recruited in the present study. Patients with esophagogastric variceal bleeding due to HBV infection-associated PH who underwent TIPS were enrolled. Stool samples were obtained before and one month after TIPS treatment, and GM was analyzed using 16S ribosomal RNA amplicon sequencing.
Results: One month after TIPS placement, 8 patients developed hepatic encephalopathy (HE) and were assigned to the HE group; the other 22 patients were assigned to the non-HE group. There was no substantial disparity in the abundance of GM at the phylum level between the two groups, regardless of TIPS treatment (all, P > 0.05). However, following TIPS placement, the following results were observed: (1) The abundance of Haemophilus and Eggerthella increased, whereas that of Anaerostipes , Dialister , Butyricicoccus , and Oscillospira declined in the HE group; (2) The richness of Eggerthella , Streptococcus , and Bilophila increased, whereas that of Roseburia and Ruminococcus decreased in the non-HE group; and (3) Members from the pathogenic genus Morganella appeared in the HE group but not in the non-HE group.
Conclusion: Intestinal microbiota-related synergism may predict the risk of HE following TIPS placement in patients with HBV-related PH. Prophylactic microbiome therapies may be useful for preventing and treating HE after TIPS placement.
Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
(©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
- References:
J Clin Med. 2021 Jun 12;10(12):. (PMID: 34204748)
Front Cell Infect Microbiol. 2019 May 22;9:167. (PMID: 31231616)
Cureus. 2022 May 31;14(5):e25537. (PMID: 35800791)
Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):821-834. (PMID: 28650209)
Ann Gastroenterol. 2023 Mar-Apr;36(2):141-148. (PMID: 36864944)
Intern Emerg Med. 2020 Jan;15(1):37-48. (PMID: 31919780)
Zhonghua Gan Zang Bing Za Zhi. 2019 Aug 20;27(8):582-593. (PMID: 31594075)
Medicine (Baltimore). 2022 Dec 23;101(51):e32335. (PMID: 36595801)
Gut. 2020 Jul;69(7):1173-1192. (PMID: 32114503)
Gut Microbes. 2014 May-Jun;5(3):397-403. (PMID: 24690956)
J Hepatol. 2014 Sep;61(3):642-59. (PMID: 25015420)
Int J Mol Sci. 2019 Jan 17;20(2):. (PMID: 30658519)
Clin Gastroenterol Hepatol. 2019 Mar;17(4):756-765.e3. (PMID: 30036646)
Gut Microbes. 2021 Jan-Dec;13(1):1953247. (PMID: 34346283)
Infect Drug Resist. 2021 Jul 06;14:2571-2578. (PMID: 34262302)
Acta Gastroenterol Belg. 2021 Jan-Mar;84(1):87-90. (PMID: 33639698)
Nature. 2014 Sep 4;513(7516):59-64. (PMID: 25079328)
Vaccine. 2018 Feb 1;36(6):794-801. (PMID: 29306503)
Exp Ther Med. 2019 Sep;18(3):1935-1944. (PMID: 31410156)
JHEP Rep. 2022 Feb 15;4(5):100448. (PMID: 35313729)
Nat Methods. 2016 Jul;13(7):581-3. (PMID: 27214047)
J Clin Med. 2019 Feb 02;8(2):. (PMID: 30717396)
J Hepatol. 2018 Aug;69(2):406-460. (PMID: 29653741)
BMC Gastroenterol. 2013 Dec 26;13:175. (PMID: 24369878)
J Clin Med. 2021 Jan 18;10(2):. (PMID: 33477417)
J Infect. 2007 Jan;54(1):98-102. (PMID: 17049992)
Medicine (Baltimore). 2022 Aug 19;101(33):e29935. (PMID: 35984175)
Sci Rep. 2016 May 26;6:26800. (PMID: 27225869)
Gut Microbes. 2011 Mar-Apr;2(2):99-104. (PMID: 21694499)
J Vasc Interv Radiol. 2019 Feb;30(2):148-153.e2. (PMID: 30638778)
Genome Med. 2016 Apr 27;8(1):51. (PMID: 27122046)
Front Cell Infect Microbiol. 2021 Jan 21;10:595759. (PMID: 33553004)
J Surg Res. 2018 Jan;221:246-256. (PMID: 29229136)
J Hosp Infect. 2017 Aug;96(4):342-348. (PMID: 28545829)
J Hepatol. 2014 May;60(5):940-7. (PMID: 24374295)
Hepatology. 2017 May;65(5):1765-1768. (PMID: 28027582)
World J Gastroenterol. 2014 Mar 14;20(10):2704-14. (PMID: 24627607)
World J Gastroenterol. 2019 Jan 28;25(4):509-520. (PMID: 30700946)
Nat Biotechnol. 2019 Aug;37(8):852-857. (PMID: 31341288)
Biomedicines. 2023 Apr 25;11(5):. (PMID: 37238943)
- Contributed Indexing:
Keywords: Gut microbiota; Hepatic encephalopathy; Hepatitis B virus; Portal hypertension; Transjugular intrahepatic portosystemic shunt
- Accession Number:
0 (RNA, Ribosomal, 16S)
- Publication Date:
Date Created: 20240828 Date Completed: 20240828 Latest Revision: 20240918
- Publication Date:
20240919
- Accession Number:
PMC11346157
- Accession Number:
10.3748/wjg.v30.i31.3668
- Accession Number:
39193001
No Comments.